Key Metrics
CiteScore 

9.4
Impact Factor 

5 - 10
SJR 

Q1Neurology

SNIP 

1.87
Recommended pre-submission checks
Powered by 

Topics Covered on Therapeutic Advances in Neurological Disorders
Therapeutic Advances in Neurological Disorders Journal Specifications
Indexed in the following public directories
Web of Science
Scopus
DOAJ
SJR
| Overview | |
| Publisher | SAGE PUBLICATIONS LTD |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | USD 2300 |
| Publication Time | 15 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2008 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in Therapeutic Advances in Neurological Disorders ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Therapeutic Advances in Neurological Disorders
A multicentre study on predictors of relapses in AQP4-IgG NMOSD: Do titres matter?
- 1 Oct 2026
- Therapeutic Advances in Neurological Disorders
Relapsing anti-mGluR1 encephalitis with atypical temporal lobe manifestations – response to rituximab and recurrence with B-cell reconstitution
- 1 Oct 2026
- Therapeutic Advances in Neurological Disorders
Non-ischemic cerebral enhancing (NICE) lesions after extracranial carotid stenting: A case report
- 1 Oct 2026
- Therapeutic Advances in Neurological Disorders
Contraindications to endovascular treatment in acute ischemic stroke: Where evidence ends and structured reasoning begins
- 1 Oct 2026
- Therapeutic Advances in Neurological Disorders
Strategic positioning and long-term management of immune reconstitution therapies in multiple sclerosis: An expert consensus
- 1 Oct 2026
- Therapeutic Advances in Neurological Disorders
Alzheimer’s disease and olfactory dysfunction: the role of TNF-α and mechanisms involving ferritin and P-tau199 from an exploratory cross-sectional study
- 1 Oct 2026
- Therapeutic Advances in Neurological Disorders
A multicentre study on predictors of relapses in AQP4-IgG NMOSD: Do titres matter?
- 1 Oct 2026
- Therapeutic Advances in Neurological Disorders
Relapsing anti-mGluR1 encephalitis with atypical temporal lobe manifestations – response to rituximab and recurrence with B-cell reconstitution
- 1 Oct 2026
- Therapeutic Advances in Neurological Disorders
Non-ischemic cerebral enhancing (NICE) lesions after extracranial carotid stenting: A case report
- 1 Oct 2026
- Therapeutic Advances in Neurological Disorders
Contraindications to endovascular treatment in acute ischemic stroke: Where evidence ends and structured reasoning begins
- 1 Oct 2026
- Therapeutic Advances in Neurological Disorders
Strategic positioning and long-term management of immune reconstitution therapies in multiple sclerosis: An expert consensus
- 1 Oct 2026
- Therapeutic Advances in Neurological Disorders
Alzheimer’s disease and olfactory dysfunction: the role of TNF-α and mechanisms involving ferritin and P-tau199 from an exploratory cross-sectional study
- 1 Oct 2026
- Therapeutic Advances in Neurological Disorders